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Abstract
Nowaday screening of non-small cell lung cancer (NSCLC) patients for epidermal growth factor receptor (EGFR) 
activating mutations is carried out in routine diagnostics to select patients who could benefit from EGFR inhibitor 
therapies.  We aimed to compare EGFR mutation testing by Ion Torrent PGM technology, using AmpliSeq Colon and 
Lung Cancer panel, with real-time PCR in order to evaluate the accuracy of next generation sequencing (NGS) in 
detecting clinically relevant EGFR mutations in NSCLC.
In total, 368 NSCLC patient samples were tested for EGFR by PCR and were also sequenced by Ion Torrent 
PGM by using AmpliSeq Colon and Lung panel. Samples were formalin-fixed, paraffin-embedded tumor specimens 
of Finnish NSCLC patients. The mutations studied for comparison were G719X, S768I, T790M, L858R, L861Q, 
deletions in exon 19 and insertions in exon 20.
Comparison of EGFR mutations detectable by both PCR kit and NGS panel, showed a high degree of concordance 
between the two methods. Out of 368 samples, 31 out of 32 positive by PCR were also positive by NGS, and 336 out 
of 336 negative by PCR for these mutations were also negative by NGS giving a concordance of 99.7%. Two negative 
samples by PCR showed insertions in exon 20, which were not detectable by PCR. In one sample NGS failed to 
detect G719X mutation that had a very weak signal in PCR.
Our study shows that the Ion Torrent PGM technology gives highly comparable results with the golden standard 
PCR. Thus, this NGS methodology is sensitive and reliable while testing clinically and diagnostically significant EGFR 
mutations in FFPE samples. 
Keywords: Non-small cell lung cancer; Epidermal growth factor 
receptor; Mutation; Next generation sequencing; Ion Torrent; PCR 
Introduction
The differences in molecular features of tumors and their predictive 
role in the response to targeting treatment have become very evident in 
the last decade. The alterations can be divided into groups based on a 
type of study they are approached with: protein, RNA and DNA-based 
methods. The last is used to assess mutations in the genome. In 2004, 
activating EGFR mutations and their role in the response to EGFR 
tyrosine kinase inhibitors (TKI) were described [1-3]. Since then many 
driver mutations in multiple genes, such as in ALK, and RAS and HER 
family, have been described, but EGFR mutations are still among the 
most common biomarkers in non-small-cell lung cancer (NSCLC). 
Currently the US Food and Drug Administration (FDA) has approved 
three different targeted therapies, afatinib, erlotinib and gefitinib, for 
advanced NSCLC harboring activating mutations most importantly 
EGFR exon 19 deletions or exon 21 substitution L858R [4].
There are also some other EGFR mutations with a clinical interest, 
such as G719X, L861Q and S768I, which have been associated with a 
good or partial response to EGFR-TKIs [5,6]. However, the development 
of resistance to EGFR-TKIs is common in the course of treatment. For 
instance, the acquired EGFR mutation T790M or MET amplification 
can cause the insensitivity to EGFR-TKIs after the preliminary good 
response [7-9]. Also insertions in exon 20 involving the residues A767, 
S768, D770, P772 and H773 show lack of response when treated with 
gefitinib or erlotinib [5,10]. Thus, it would be important to test patients’ 
genetic alterations with the multiplex and sensitive methods.
PCR-based mutation testing kits and Sanger sequencing have 
become as golden standard methods for diagnostic purposes. Next 
generation sequencing (NGS) methods are fast, economical, sensitive 
and multiplexable, and they are slowly replacing the traditional 
methods. However, before implementation of NGS in diagnostic 
settings, it is important to thoroughly test and compare results to those 
with standard routine diagnostic methods. Some previous studies have 
shown the Ion Torrent PGM system to be accurate in mutation analysis 
by using the Ion AmpliSeq Colon and Lung cancer Panel and/or the Ion 
AmpliSeq Colon and Lung Cancer Research Panel V2 compared with 
Sanger sequencing [11,12], the Ion AmpliSeq™ Cancer Panel compared 
with direct sequencing of peptide nucleic acid-locked nucleic acid 
polymerase chain reaction (PNA-LNA PCR) product [13] and custom 
panel of cancer genes compared with Sanger sequencing [14], although 
these have been performed on smaller sample sizes. In this study, we 
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Ion Torrent AmpliSeq Sequencing
Ten nanogram of DNA were used to prepare the barcoded libraries 
with the Ion AmpliSeq™ Library kit 2.0 (Thermo Fisher Scientific). 
The Colon and Lung Cancer panel covered 504 mutational hotspots 
and targeted regions (totaling 14.6 kb) in 22 genes, including EGFR. 
Template preparation and enrichment was performed with the Ion 
OneTouch™ 2 System (Thermo Fisher Scientific). Finally, sequencing 
was carried out using Ion 316™ chips on the Ion Personal Genome 
Machine System (PGM™, Thermo Fisher Scientific) and with the Ion 
PGM™ Sequencing 200 kit v2 (Thermo Fisher Scientific).
Alignment to the hg19 human reference genome and variant calling 
was performed by the Torrent Suite Software v.4.0.2 (Thermo Fisher 
Scientific) by the default threshold settings. For quality scores, coverage 
and strand biases those were a quality score of minimum of 6, relative 
read quality of minimum of 6.5, coverage of minimum of 6 for SNP/
COSMIC variant and 15 for indel, and strand bias maximum of 95% 
for SNP/COSMIC variant and 90% for indel. Alignments were visually 
checked with the Integrative Genomics Viewer (IGV) (v.2.3.34, Broad 
Institute) [17].
Results & Discussion
We compared the EGFR mutation detection in 368 NSCLC FFPE 
tumor samples between the real-time PCR method and the amplicon-
based Ion Torrent PGM sequencing technology (Tables 2 and 3). The 
mutations were detected in 9% (34/368) of the patients. The observed 
mutation status pattern was highly comparable with the results from 
other studies as illustrated in our previous study by the standard PCR 
[16]. We detected a very high concordance between the results by the 
two methods used. Comparing only those mutations detectable by 
PCR in 368 samples, 31 out of 32 positive by PCR were also positive by 
NGS, and 336 out of 336 negative by PCR for these mutations were also 
negative by NGS giving a concordance of 99.7%. When taking the PCR 
results as true positive, the number of EGFR positive by NGS, were 31 
(true positive = 31; false positive = 0) and negative 337 (true negative 
= 336; false negative = 1). The sensitivity and specificity of detecting 
clinically common mutations L858R, deletions in exon 19, insertions 
in exon 20, G719X, S768I by the Ion AmpliSeq Colon and Lung Cancer 
Panel as following: 96.9% and 100%, respectively. 
Other studies carried on relatively smaller sample size have shown a 
good concordance between PCR and NGS mutation testing [15,18,19]. 
Our results from a larger cohort clearly indicate that clinically important 
EGFR mutations can be detected with high accuracy by amplicon based 
NGS and is suitable in diagnostics. Similarly, recent comparisons 
between Sanger sequencing and NGS have shown similar results, giving 
greater sensitivity to NGS [11, 12, 15, 18-20]. Studies comparing the Ion 
compared the EGFR mutation statuses of 368 Finnish NSCLC tumor 
specimens detected by the real-time PCR method and the targeted 
amplicon-based Ion Torrent NGS by using the Colon and Lung Cancer 
Panel performed on DNA extracted from formalin-fixed, paraffin-
embedded (FFPE) tumor material in order to evaluate the accuracy of 
NGS in detecting clinically important EGFR mutations.
Material and Methods
Patients
In total, we collected retrospectively 566 FFPE tumor specimens 
obtained via either diagnosis or surgical procedures, of NSCLC patients 
treated at the Hospital District of Helsinki and Uusimaa (HUS), 
Finland, during 2006–2014. Of those, tumor DNA from 368 NSCLC 
specimens were studied for EGFR mutations by both the real-time PCR 
and the amplicon–based NGS using the Colon and Lung Cancer Panel 
with the Ion Torrent PGM sequencing technology. Tumor content and 
histological type of NSCLC were confirmed by pathologist. Tumor 
content ranged from 5 to 90%, in 90% of the samples, the content was at 
least 20%. Patient characteristics are presented in the table 1.
DNA Extraction and Mutation Detection
DNA was isolated from FFPE sections using the QIAamp DNA Mini 
kit (Qiagen GmbH, Hilden, Germany), following the manufacturer’s 
instructions, with small modifications [15]. DNA concentration was 
assessed using the Qubit® 2.0 Fluorometer (Thermo Fisher Scientific).
PCR Analysis
In our previous study, the tumor DNA samples of over 500 NSCLC 
patients were tested for EGFR mutations by using the Therascreen EGFR 
PCR Kit (Qiagen®, Manchester, UK) according to the manufacturer’s 
protocol, on the ABI7500 platform or the cobas® EGFR Mutation Test 
(Roche Molecular Systems, South Branchburg, USA) according to the 
manufacturer’s protocol, on the cobas® z480 platform [16]. Of those, 
368 samples were studied also by Ion Torrent and in this study we 
compare the results.
Feature N (%)
Histology
ADC 265 (72)
SCC 58 (16)
LCC 28 (8)
ADSQ 11 (3)
Other NSCLC 6 (2)
Gender
Male 211 (57)
Median age, years 66
Smokinga
Never-smoker 31 (8)
Light ex-smoker 29 (8)
Medium ex-smoker 133 (36)
Current smoker 170 (46)
NA 5 (1)
Abbreviations: ADC: Adenocarcinoma; LCC: Large Cell Carcinoma; SCC: 
Squamous Cell Carcinoma; ADSQ: Adenosquamous Carcinoma; NSCLC: Non-
Small Cell Lung Cancer
alight ex-smoker: smoking <20 years, cessation >10 years ago; medium ex-
smoker: smoking >20 years, ceased; and current smoker: current smokers, 
smoking >20 years
Table 1: The characteristics of the patients included into this study. 
Mutation Detected by PCR Detected by NGS
L858R 15 15
Deletion in exon 19 12 12
G719X 4 3
G719X & S768I 1 1
Insertion in exon 20 0 2a
Other COSMIC mutationa 0 12
No mutations 336 322
Total 368 368
aNot detectable by Therascreen EGFR mutation testing.
Table 2: The comparison of EGFR mutation result between PCR and AmpliSeq 
colon and lung panel.
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S. No Patient Mutation by PCR Mutation by NGS Mutant read frequency, % (NGS) Tumor content, %
1 359 L858R L858R 14 20
2 66 L858R L858R 37 55
3 505 L858R L858R 6 20
4 546 L858R L858R 74 45
5 203 L858R L858R 25 40
6 217 L858R L858R 5 35
7 157 L858R L858R 10 40
8 160 L858R L858R 30 55
9 105 L858R L858R 21 35
10 27 L858R L858R 16 30
11 560 L858R L858R 11 30
12 554 L858R L858R 3 10
13 486 L858R L858R 44 60
14 671 L858R L858R 17 70
15 603 L858R L858R 3 10
16 233 Del Ex19 Del Ex19 60 35
17 199 Del Ex19 Del Ex19 34 50
18 508 Del Ex19 Del Ex19 31 65
19 215 Del Ex19 Del Ex19 a 10 30
20 52 Del Ex19 Del Ex19 10 35
21 211 Del Ex19 Del Ex19 55 70
22 70 Del Ex19 Del Ex19 33 45
23 631 Del Ex19 Del Ex19b 28 55
24 653 Del Ex19 Del Ex19 12 15
25 587 Del Ex19 Del Ex19 26 60
26 646 Del Ex19 Del Ex19 54 70
27 632 Del Ex19 Del Ex19 18 10
28 239 G719X G719X 42 55
29 107 G719X no mutationc 0 70
30 234 G719X G719X 37 50
31 688 G719X G719A 37 30
32 672 G719X; S768I G719A; S768I 12; 11 45
33 166 No mutationd D770_N771insSVD 24 75
34 580 No mutationd D770_N771insSVD 23 30
35 513 No mutation S720F; A767V 3; 6 60
36 467 No mutation V774M 8 45
37 350 No mutation S784F 3 40
38 236 No mutation A864T 2 70
39 34 No mutation A864T 3 60
40 311 No mutation D770N 3 15
41 521 No mutation P741L 3 25
42 534 No mutation V765M 2 70
43 344 No mutation A871T 4 90
44 244 No mutation A871T; G874S 4; 4 50
45 674 No mutation R776H 3 40
aMissed by Ion Torrent Software, but seen clearly by visualization in 9.9% of the reads.
bNovel 2bp deletion followed by 10bp deletion.
cDetected by Therascreen, but is uncertain with weak signal.
dNot detectable by Therascreen EGFR mutation testing kit. 
Table 3: The patients with EGFR mutations detected by either method.
Torrent technology are also in concordance with this study, suggesting 
it to be eligible method in diagnostics [11,12,19].
The comparison of the two methods showed discrepant results in 
two samples. One patient with EGFR deletion by PCR, was missed by 
the Ion Torrent software (probably filtered out by the variant calling 
setting), although it was clearly seen in 10% of reads with IGV. Another 
patient with G719X mutation in PCR was clearly negative for this 
mutation by NGS even though the read depth at this location was 2204x. 
Since, this sample had a very low concentration in PCR (Ct 38.97 and 
dCt 11.70) and was flagged as doubtful; it is not certain whether it is 
false positive in PCR or false negative in NGS. 
One important parameter of considerable significance in detecting 
mutations in tumor samples by NGS is deciding appropriate cut-off for 
mutation allele frequency, so as it maximizes sensitivity and minimizes 
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false positive rate. Since the proportion of tumor cells in tumor samples 
can vary greatly among different samples, it can greatly affect the 
mutant allele proportion. We therefore also analyzed the tumor content 
of sample, as estimated histologically, in relation to percent of mutant 
allele among total reads. Overall, the percentage of mutant reads ranged 
between 3 and 75% (average 28%) for all EGFR mutation. In this study, 
we could successfully detect EGFR mutations in samples with tumor 
content of 10% that had mutant reads percentage ranging between 3 and 
18. At a cut-off of 3% for reads with mutant allele, we could detect all 
clinically relevant mutations without any false positives. This suggests 
NGS to be a sensitive method and can detect mutant alleles as low as 
3% of the reads without false positives. Previous study has reported 
the limit of detection 1.3% or less for the Ion Torrent AmpliSeq panel 
[20]. Percentage of mutant reads was positively co-related to tumor 
percentage, though not very strongly (Pearson’s correlation R=0.5). At 
least five samples had mutant reads more than 50% that could indicate 
a probable amplification of the mutant EGFR allele.
In addition to EGFR mutations that could be detected by both PCR 
and NGS, 12 patients had other COSMIC mutations detected by NGS, 
but not seen by PCR as they are not included in the PCR panel. This is a 
great advantage of NGS to detect all kind of mutations and distinguish 
them. By NGS, for instance, exon 19 deletions and exon 20 insertions 
are detectable in more detail, as PCR cannot distinguish them. By NGS 
we were able to identify two samples with exon 20 insertions (p.D770_
N771insSVD) which were not detected by PCR, because it is not 
included in the PCR panel (Figure 1). Mutant reads were around 20% 
in both these cases by NGS. Similarly, we detected novel 2bp deletion in 
patient 631, which is not described previously. Although, this deletion 
was detected by PCR it did not identify it (since it only detects deletions 
without characterizing them). Moreover, we could clearly identify 
different variations of exon 19 deletion with NGS (Figure 2).
Another strength of the amplicon based Ion Torrent NGS is the 
sufficiency of small amount of starting material (ten nanogram of 
DNA), and its applicability to FFPE specimens. Moreover, Ion Torrent 
NGS workflow is user-friendly and fast.
 
Figure 1: IGV visualization of insertion P.D770_N771insSVD detected by 
NGS, but not by PCR. 
 
Figure 2: IGV visualization of four different exon 19 deletions. 
 c.HMB 45 stain 
staiststain
Conclusion
As conclusion, this study shows that the Ion Torrent technology 
gives highly comparable results with the golden standard PCR. Thus, 
this NGS methodology is sensitive and reliable while testing clinically 
and diagnostically important EGFR mutations from FFPE samples.
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